Co-promotion Deals – Panacea or Poison Pill?

The incidence of co-promotion components in biotechnology/pharmaceutical licensing deals for development products has grown steadily since 1996 according to data from PharmaDeals© V4. In 1996 just 6% of licensing deals retained co-promotion rights or options for licensors, to date in 2010 the frequency is double that (12%). We were interested to uncover if these agreements converted into commercial realities and if so did they turn out to be mutual successes for the concerned parties.